TY - JOUR
T1 - Overall survival and patterns of care for women with rare ovarian cancers: A prospective study from the Australian National Gynae-Oncology Registry (NGOR).
T2 - Journal of Clinical Oncology
AU - Naidoo, Mahendra
AU - Scott, Clare L.
AU - McNally, Orla
AU - Rome, Rob
AU - Perera, Sharnel
AU - Lee, Yeh Chen
AU - Whitely, Aleesha
AU - Burling, Michael
AU - Anderson, Lyndal
AU - Cohen, Paul
AU - Richardson, Gary Edward
AU - Friedlander, Michael
AU - Brand, Alison
AU - Hyde, Simon
AU - Bunting, Michael
AU - Jobling, Tom
AU - Zalcberg, John Raymond
N1 - doi: 10.1200/JCO.2024.42.16_suppl.e17554
PY - 2024/5/29
Y1 - 2024/5/29
N2 - e17554Background: Ovarian cancer (OC) is a heterogenous group of malignancies, most of which are rare. Data on patterns of care and survival of the most-rare sub-groups of OC (incidence rates < 6 per 100,000) in the real-world setting is limited. This study aims to describe patterns of care and overall survival (OS) for women with rare ovarian cancers in Australia. Methods: Clinical data were sourced from the NGOR and assessed for accuracy and completeness. High grade serous and endometrioid OC subtypes were excluded. Due to incompleteness of survival follow-up data, 3-year OS was only calculated for the state of Victoria. Results: Data on 2812 women with newly diagnosed OC from 2017-2023 within NGOR were collected and 716 women were subsequently identified with rare subtypes of OC. The 5 sub-types with the highest incidences were clear cell (n = 168, 23.4%), mucinous (n=151, 21.1%), adult granulosa cell (n=111, 15.5%), low grade serous (n=98, 13.7%) and carcinosarcoma (n=59, 8.2%). A further 23 additional rare subtypes included germ cell tumours and sex cord stromal tumours. The median follow-up time was 2.6 years and median age at diagnosis was 55 years. Most women had an ECOG 0-1 performance status (n=551, 77.0%). The primary treatment modality was surgery only (n=360, 50%), followed by surgery and systemic therapy (n = 317, 44.2%), systemic therapy only (n=28, 3.9%) and no treatment (n=11, 1.5%). Most women were discussed at a multi-disciplinary meeting (n=701, 97.9%). The diagnosis was confirmed on histology for all women. The 30-day post-operative adverse events (Clavien-Dindo >III severity) was 3.6 % (n=26), with the highest rate of post-operative events in the carcinosarcoma group of 12% (n=6). Using Fisher?s exact test across the 5 most common sub-types described above, there were significant differences in treatment modalities (p
AB - e17554Background: Ovarian cancer (OC) is a heterogenous group of malignancies, most of which are rare. Data on patterns of care and survival of the most-rare sub-groups of OC (incidence rates < 6 per 100,000) in the real-world setting is limited. This study aims to describe patterns of care and overall survival (OS) for women with rare ovarian cancers in Australia. Methods: Clinical data were sourced from the NGOR and assessed for accuracy and completeness. High grade serous and endometrioid OC subtypes were excluded. Due to incompleteness of survival follow-up data, 3-year OS was only calculated for the state of Victoria. Results: Data on 2812 women with newly diagnosed OC from 2017-2023 within NGOR were collected and 716 women were subsequently identified with rare subtypes of OC. The 5 sub-types with the highest incidences were clear cell (n = 168, 23.4%), mucinous (n=151, 21.1%), adult granulosa cell (n=111, 15.5%), low grade serous (n=98, 13.7%) and carcinosarcoma (n=59, 8.2%). A further 23 additional rare subtypes included germ cell tumours and sex cord stromal tumours. The median follow-up time was 2.6 years and median age at diagnosis was 55 years. Most women had an ECOG 0-1 performance status (n=551, 77.0%). The primary treatment modality was surgery only (n=360, 50%), followed by surgery and systemic therapy (n = 317, 44.2%), systemic therapy only (n=28, 3.9%) and no treatment (n=11, 1.5%). Most women were discussed at a multi-disciplinary meeting (n=701, 97.9%). The diagnosis was confirmed on histology for all women. The 30-day post-operative adverse events (Clavien-Dindo >III severity) was 3.6 % (n=26), with the highest rate of post-operative events in the carcinosarcoma group of 12% (n=6). Using Fisher?s exact test across the 5 most common sub-types described above, there were significant differences in treatment modalities (p
U2 - 10.1200/JCO.2024.42.16_suppl.e17554
DO - 10.1200/JCO.2024.42.16_suppl.e17554
M3 - Abstract/Meeting Abstract
SN - 0732-183X
VL - 42
SP - e17554-e17554
JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
IS - 16 Suppl
ER -
